logo-loader
viewhVIVO PLC

hVIVO keen to expand challenge trials presence into new indications

Snapshot

The challenge trial charts the entire disease life cycle from healthy to sick and back to health.

Challenge trials can speed up vaccine development

Quick facts: hVIVO PLC

Price: 13.5 GBX

LSE:HVO
Market: LSE
Market Cap: £11.24 m
Follow

 

  • hVIVO PLC (LON:HVO) has developed a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases

  • Company is also developing a flu vaccine, FLU-v, through a joint venture with SEEK Group

  • Gearing up to take Flu-v into phase III trial

 

What it does

Using challenge trials, hVIVO helps drug companies researches influenza (flu), respiratory syncytial virus (RSV), human rhinovirus (HRV) and respiratory indications.

The trial chart the entire disease life cycle from healthy to sick and back to health.

The company is expanding its expertise into airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) and coughs.

Flu vaccine

HVIVO is also developing a flu vaccine, FLU-v, through a joint venture with SEEK Group.

A phase II trial met its primary endpoint of statistical significance in symptom reduction.

The JV is looking for a partner to help fund the cost of what will be a sizeable phase III trial.

Currently, flu vaccines have to be redesigned every year as the flu virus evolves rapidly.

One of the major plus-points for FLU-v is that it offers long-lasting protection against a broad spectrum of influenza which hVIVO believes could be given to a much broader population.

How is it doing

 Revenues of £5.9mln in the six months ended June 30, up £1mln year-on-year, or 20%.

The adjusted operating loss narrowed by more than a quarter to £3.7mln, while research and development spend fell by 60% to just £1.1mln.

hVIVO had cash and equivalents of £4mln at the period-end, supplement by an R&D credit worth £2.4mln that was paid earlier this month.

The statement added there had been an “unprecedented levels of contract cancellations”, due to client portfolio prioritisation, that had hit the cash position at “a time when business turnaround and efficiencies are still to be fully realised.

What the boss says, Trevor Phillips, executive chairman

"We have made progress in expanding our service offerings to enhance revenue opportunities, delivered further successful client studies and extend our position as a leader in viral challenge studies,” 

Video

 

Inflexion points

  • Partner for Flu-v vaccine to help fund phase IlI trial
  • Expansion of challenge trials into new areas such as COPD and asthma
  • New contracts for challenge trials in elderly patients 

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

on 19/9/19

2 min read